Sepracor Sues Synthon Over Oral Xyzal ANDA
A patent spat over antihistamine Xyzal has flared up again, with Belgian drugmaker UCB SA and its U.S. partner Sepracor Inc. launching a new suit against Synthon Pharmaceuticals Inc. over its...To view the full article, register now.
Already a subscriber? Click here to view full article